FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FIER IAN		 2. Issuer Name and Ticker or Trading Symbol

MOMENTA PHARMACEUTICALS INC [ MNTA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Mfg and Program Officer
(Last)          (First)          (Middle)

C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/1/2020
(Street)

CAMBRIDGE, MA 02142
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units  (1)10/1/2020  D     45000   (1) (1)Common Stock 45000  (1)0 D  
Restricted Stock Units  (1)10/1/2020  D     1425   (1) (1)Common Stock 1425  (1)0 D  
Restricted Stock Units  (1)10/1/2020  D     21938   (1) (1)Common Stock 21938  (1)0 D  
Restricted Stock Units  (1)10/1/2020  D     40000   (1) (1)Common Stock 40000  (1)0 D  
Stock Option (Right to Buy) $18.85 10/1/2020  D     2751   (2)2/7/2027 Common Stock 2751  (2)0 D  
Stock Option (Right to Buy) $12.76 10/1/2020  D     20192   (2)2/11/2029 Common Stock 20192  (2)0 D  
Stock Option (Right to Buy) $31.87 10/1/2020  D     3622   (2)2/7/2030 Common Stock 3622  (2)0 D  
Stock Option (Right to Buy) $18.85 10/1/2020  D     99   (2)2/7/2027 Common Stock 99  (2)0 D  
Stock Option (Right to Buy) $12.76 10/1/2020  D     52808   (2)2/11/2029 Common Stock 52808  (2)0 D  
Stock Option (Right to Buy) $31.87 10/1/2020  D     76378   (2)2/7/2030 Common Stock 76378  (2)0 D  
Explanation of Responses:
(1) Reflects disposition of Issuer restricted stock units in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price").
(2) Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
FIER IAN
C/O MOMENTA PHARMACEUTICALS, INC.
301 BINNEY STREET
CAMBRIDGE, MA 02142

Chief Mfg and Program Officer
Signatures
/s/ R. Mark Chamberlin as attorney in fact10/1/2020
**Signature of Reporting PersonDate
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Momenta Pharmaceuticals Charts.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Momenta Pharmaceuticals Charts.